Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Burkitt Lymphoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Biphenotypic, Acute 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Drug-Related Side Effects and Adverse Reactions 3Neoplasms 2Neoplasm Metastasis 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hematologic Neoplasms 2Brain Neoplasms 2Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Pneumonia 1Oropharyngeal Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Hepatectomy 1Down Syndrome 1Cranial Nerve Diseases 1

Interventions

Cyclophosphamide 11Dexamethasone 10Cytarabine 10Vincristine 8Methotrexate 7merphos 5Mercaptopurine 5Doxorubicin 5venetoclax 4pegaspargase 4dexamethasone acetate 4dexamethasone 21-phosphate 4blinatumomab 4azathiopurine 4auricularum 4Specimen Handling 4Prednisone 4Leucovorin 4Inotuzumab Ozogamicin 4Calcium Dobesilate 4prednylidene 3deltacortene 3Thioguanine 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Methylprednisolone 3Asparaginase 3calaspargase pegol 2asparaginase erwinia chrysanthemi recombinant 2Spinal Puncture 2Rituximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Methylprednisolone × 1 year × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT05303792 2026-04-07

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
68 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡